Get the Stockscreener App
16.90
6.53%
-1.18
After Hours:
16.91
0.01
+0.06%
Adaptive Biotechnologies Corp stock is traded at $16.90, with a volume of 2.16M.
It is down -6.53% in the last 24 hours and up +22.64% over the past month.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
See More
Previous Close:
$18.08
Open:
$17.9
24h Volume:
2.16M
Relative Volume:
1.10
Market Cap:
$2.70B
Revenue:
$295.41M
Net Income/Loss:
$-49.64M
P/E Ratio:
-51.62
EPS:
-0.3274
Net Cash Flow:
$-29.54M
1W Performance:
+11.55%
1M Performance:
+22.64%
6M Performance:
+14.58%
1Y Performance:
+71.23%
1-Day Range:
$16.68
$18.29
1-Week Range:
$14.74
$18.29
52-Week Range:
$9.90
$20.76
Adaptive Biotechnologies Corp Stock (ADPT) Company Profile
Name
Adaptive Biotechnologies Corp
Sector
Industry
Phone
206-659-0067
Address
1165 EASTLAKE AVE E, SEATTLE, WA
Compare ADPT vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADPT
Adaptive Biotechnologies Corp
|
16.90 | 2.89B | 295.41M | -49.64M | -29.54M | -0.3274 |
TMO
Thermo Fisher Scientific Inc
|
472.80 | 179.13B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
184.30 | 132.10B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
562.16 | 44.55B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
135.44 | 39.08B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
365.36 | 36.96B | 3.77B | 449.25M | 240.68M | 7.8556 |
Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-25 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-30-25 | Initiated | Guggenheim | Buy |
| Jun-18-25 | Initiated | Craig Hallum | Buy |
| Mar-21-25 | Upgrade | Goldman | Neutral → Buy |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Dec-21-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-25-22 | Initiated | Credit Suisse | Underperform |
| Jun-03-22 | Initiated | Piper Sandler | Neutral |
| Feb-16-22 | Reiterated | BTIG Research | Buy |
| Feb-16-22 | Reiterated | BofA Securities | Buy |
| Feb-16-22 | Reiterated | Goldman | Neutral |
| Feb-16-22 | Reiterated | JP Morgan | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Mar-03-21 | Downgrade | Goldman | Buy → Neutral |
| Oct-08-20 | Resumed | BTIG Research | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-03-20 | Initiated | Goldman | Buy |
| Jul-23-19 | Initiated | BTIG Research | Buy |
| Jul-22-19 | Initiated | BofA/Merrill | Buy |
| Jul-22-19 | Initiated | Cowen | Outperform |
| Jul-22-19 | Initiated | Goldman | Neutral |
| Jul-22-19 | Initiated | Guggenheim | Buy |
| Jul-22-19 | Initiated | William Blair | Outperform |
View All
Adaptive Biotechnologies Corp Stock (ADPT) Latest News
[144] Adaptive Biotechnologies Corp SEC Filing - Stock Titan
ADPT (NASDAQ: ADPT) affiliate notifies planned sale after option exercise - Stock Titan
How The Adaptive Biotechnologies (ADPT) Narrative Is Shifting Around A US$20 Fair Value Anchor - Yahoo Finance
Adaptive Biotechnologies Highlights clonoSEQ Growth, 2026 Cash Flow Goal at Conference - Yahoo Finance
Adaptive Biotech (ADPT) Reports 35% Revenue Growth Driven by Strong clonoSEQ Performance in Q1 2026 - Insider Monkey
10 Best Growth Stocks Under $20 to Buy - Insider Monkey
Does ADPT’s clonoSEQ Spotlight at ASCO and EHA Reveal a Durable MRD Moat in Oncology? - simplywall.st
Jupiter Asset Management Ltd. Acquires 91,683 Shares of Adaptive Biotechnologies Corporation $ADPT - MarketBeat
Adaptive Biotechnologies Hits Day High with 9.75% Surge in Stock Price - Markets Mojo
Adaptive Biotechnologies Announces Extensive Presence at ASCO and EHA Conferences Showcasing clonoSEQ Test for MRD Assessment - Quiver Quantitative
Blood cancer monitoring test featured in 33 studies at major oncology meetings - Stock Titan
Harvest Investment Services Dumps 356,000 Adaptive Biotechnologies (ADPT) Shares Worth $5.7 Million - AOL.com
Harvest Investment Services Dumps 356,000 Adaptive Biotechnologies (ADPT) Shares Worth $5.7 Million - The Motley Fool
ADPT SEC FilingsAdaptive Biotechnologies 10-K, 10-Q, 8-K Forms - Stock Titan
Hear Adaptive Biotechnologies' June 3 investor talk live online - Stock Titan
Adaptive Biotechnologies CFO Kyle Piskel sells $40,619 in stock By Investing.com - Investing.com Canada
Adaptive Biotechnologies CFO Kyle Piskel sells $40,619 in stock - Investing.com
Adaptive Biotechnologies (ADPT) CFO tax-related share sale leaves 256,725 shares held - Stock Titan
UBS Group AG Purchases 257,947 Shares of Adaptive Biotechnologies Corporation $ADPT - MarketBeat
Adaptive Biotechnologies Corp at TD Cowen Healthcare Conference Transcript - GuruFocus
Proposed sale of 3,160 RSUs by ADPT (NASDAQ: ADPT) reported - Stock Titan
Viking firms hold 18.8% of Adaptive Biotechnologies (NASDAQ: ADPT) - Stock Titan
ADPT Stock Price, Quote & Chart | ADAPTIVE BIOTECHNOLOGIES (NASDAQ:ADPT) - ChartMill
ADPT Maintained by Morgan Stanley -- Price Target Lowered to $18 - GuruFocus
Morgan Stanley Cuts Adaptive Biotechnologies (NASDAQ:ADPT) Price Target to $18.00 - MarketBeat
Assessing Adaptive Biotechnologies (ADPT) Valuation After Strong MRD Growth And Raised Full Year Guidance - Yahoo Finance
Analysts Expect Breakeven For Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Before Long - Moomoo
How Strong MRD Growth and Upgraded 2026 Guidance Will Impact Adaptive Biotechnologies (ADPT) Investors - simplywall.st
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q1 2026 Earnings Call Transcript - Insider Monkey
Adaptive Biotech Q1 2026 slides: MRD revenue surges 53%, guidance raised - Investing.com Australia
Adaptive Biotechnologies Corporation 10-Q Report 2026: Financial Statements, Risk Factors, and Forward-Looking Statements 173031 - Minichart
Adaptive Biotech Q1 2026 slides: MRD revenue surges 53%, guidance raised By Investing.com - Investing.com South Africa
Earnings call transcript: Adaptive Biotechnologies Q1 2026 revenue beats forecast By Investing.com - Investing.com South Africa
Adaptive Biotechnologies (ADPT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
Earnings call transcript: Adaptive Biotechnologies Q1 2026 revenue beats forecast - Investing.com
Transcript: Adaptive Biotechnologies Q1 2026 Earnings Conference Call - Benzinga
Adaptive Biotechnologies: Q1 Earnings Snapshot - marketscreener.com
Adaptive Biotechnologies Corp reports results for the quarter ended March 31Earnings Summary - TradingView
[10-Q] Adaptive Biotechnologies Corp Quarterly Earnings Report - Stock Titan
Q1 2026 Adaptive Biotechnologies Corp Earnings Call Transcript - GuruFocus
Adaptive Biotechnologies Corp Stock (ADPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.13%
2.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):